Evidence map›Paper›PMID 32444984›Full record

SynthesisJournal of neurology2020

A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project.

Sandra Lopez-Leon, Yvonne Geissbühler, Meritxell Sabidó, Moise Turkson, Charlotte Wahlich, Joan K Morris

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
9.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. [Clinical and obstetric characteristics in women with multiple sclerosis during pregnancy].Revista medica del Instituto Mexicano del Seguro Social · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Inflammatory bowel disease in pregnancy and breastfeeding.Nature reviews. Gastroenterology & hepatology · 2023
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Family planning and multiple sclerosis - Part 1: Patient perspectives on treatment choices in Sweden.Multiple sclerosis journal - experimental, translational and clinical
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 4 countries.

Sandra Lopez-LeonNovartis Pharmaceuticals Corporation, One Health Plaza, Building 339-1131, East Hanover, NJ, 07936-1080, USA. sandra.lopez@novartis.com.ORCID http://orcid.org/0000-0001-7504-3441
Yvonne GeissbühlerNovartis Pharma AG, Basel, Switzerland.
Meritxell SabidóGlobal Epidemiology, Merck KGaA, Darmstadt, Germany.
Moise TurksonCognizant Solution, London, UK.
Charlotte WahlichPopulation Health Research Institute, St George's, University of London, London, UK.
Joan K MorrisPopulation Health Research Institute, St George's, University of London, London, UK. jmorris@sgul.ac.uk.ORCID http://orcid.org/0000-0002-7164-612X
Novartis (Switzerland) · CHSt George's, University of London · GBCognizant (United Kingdom) · GBMerck (Germany) · DE

Funding

Innovative Medicines Initiative 2 821520
6 · The paper itself

Abstract

Neurologists managing women with Multiple Sclerosis (MS) need information about the safety of disease modifying drugs (DMDs) during pregnancy. However, this knowledge is limited. The present study aims to summarize previous studies by performing a systematic review and meta-analyses. The terms "multiple sclerosis" combined with DMDs of interest and a broad profile for pregnancy terms were used to search Embase and Medline databases to identify relevant studies published from January 2000 to July 2019.1260 studies were identified and ten studies met our inclusion criteria. Pooled risk ratios (RR) of pregnancy and birth outcomes in pregnancies exposed to DMDs compared to those not exposed were calculated using a random effects model. For spontaneous abortion RR = 1.14, 95% CI 0.99-1.32, for preterm births RR = 0.93, 95% CI 0.72-1.21 and for major congenital malformations RR = 0.86, 95% CI 0.47-1.56. The most common major congenital malformations reported in MS patients exposed to MS drugs were atrial septal defect (ASD) (N = 4), polydactyly (N = 4) and club foot (N = 3), which are among the most prevalent birth defects observed in the general population. In conclusion, interferons, glatiramer acetate or natalizumab, do not appear to increase the risk for spontaneous abortions, pre-term birth or major congenital malformations. There were very few patients included that were exposed to fingolimod, azathioprine and rituximab; therefore, these results cannot be generalized across drugs. Future studies including internal comparators are needed to enable treating physicians and their patients to decide on the best treatment options.

Indexed as

Abortion, SpontaneousMultiple SclerosisFemaleGlatiramer AcetateHumansInfant, NewbornNatalizumabPregnancyGlatiramer AcetateNatalizumabCongenital malformationsMultiple sclerosisPregnancyPretermSpontaneous abortions

Identifiers

PMID32444984
PMCPMC7419441
OpenAlexW3026321504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.